Corticosteroid Therapy for Persistent Synovitis in Acute Septic Arthritis on Native Joint

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05531227

Acronym

SYNOVITIS

Enrollment

100

Registered

2022-09-07

Start date

2022-06-20

Completion date

2023-12-13

Last updated

2023-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Septic

Keywords

Arthritis, Septic, synovitis, Corticosteroid therapy, Inflammatory response, Native joint

Brief summary

Acute septic arthritis is a rare but life-threatening and functionally serious disease. The improvement or disappearance of pain and functional recovery are sometimes difficult to obtain, with in some cases the persistence of synovitis due to a prolonged local inflammatory response, despite early and effective treatment. The consequences are significant for patients with often significant chronic pain, repercussions on autonomy and/or profession. An unfavorable evolution with joint destruction and need for replacement by a prosthesis is not uncommon. Corticosteroid therapy is widely used in rheumatology in similar tables, for the purpose of drug synovectomy, with good results. The risk of infection remains the main contraindication to its use. There are very few studies on its use in septic arthritis, either fundamentally or in humans, for which there are no data in adults. However, these have shown results encouraging the investigators not to neglect this therapy.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Adult patient (≥18 years old) * having presented with septic arthritis and treated at the Strasbourg University Hospital between January 1, 2012 and December 31, 2021 * clinical finding of persistent synovitis, defined by the presence of pain, effusion or joint stiffness despite well-conducted treatment * having had a diagnosis of joint infection proven by a positive culture of the joint fluid to a pathogenic germ * having had treatment with local or systemic corticosteroids.

Exclusion criteria

* Patient who has expressed his opposition to the reuse of his data for scientific research purposes. * Absence of corticosteroid treatment

Design outcomes

Primary

Measure	Time frame
Complete regression of the pain in a fast way	6 months after treatment with corticosteroids

Countries

France

Contacts

Primary ContactJeannot GAUDIAS, MD

jeannot.gaudias@chru-strasbourg.fr33 3 68 76 50 64

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr

Outcome results